Cargando…

Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial

Multidrug-resistant (MDR) Gram-negative organisms are a burden on the global health care system. The Tigecycline Evaluation and Surveillance Trial (TEST) is an ongoing global study designed to monitor the in vitro activities of tigecycline and a panel of marketed antimicrobials against a range of cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giammanco, Anna, Calà, Cinzia, Fasciana, Teresa, Dowzicky, Michael J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5244261/ https://www.ncbi.nlm.nih.gov/pubmed/28124025 http://dx.doi.org/10.1128/mSphere.00310-16

Ejemplares similares

Assessment of the Activity of Tigecycline against Gram-Positive and Gram-Negative Organisms Collected from Italy between 2012 and 2014, as Part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
por: Stefani, Stefania, et al.
Publicado: (2016)

The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016
por: Decousser, Jean-Winoc, et al.
Publicado: (2018)

Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013
por: Hoban, Daryl J, et al.
Publicado: (2015)

Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010
por: Fernández-Canigia, Liliana, et al.
Publicado: (2012)

Longitudinal Assessment of Antimicrobial Susceptibility among Gram-Negative and Gram-Positive Organisms Collected from Italy as Part of the Tigecycline Evaluation and Surveillance Trial between 2004 and 2011
por: Stefani, Stefania, et al.
Publicado: (2013)

Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial
por: Vega, Silvio, et al.
Publicado: (2017)

Antimicrobial susceptibility among gram-negative isolates collected in the USA between 2005 and 2011 as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.)
por: Denys, Gerald A, et al.
Publicado: (2013)

A longitudinal assessment of antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in France between 2004 and 2012
por: Cattoir, Vincent, et al.
Publicado: (2014)

Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial
por: Morfin-Otero, Rayo, et al.
Publicado: (2015)

Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial
por: Zhang, Zhijie, et al.
Publicado: (2018)

Regional and global antimicrobial susceptibility among isolates of Streptococcus pneumoniae and Haemophilus influenzae collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) from 2009 to 2012 and comparison with previous years of T.E.S.T. (2004-2008)
por: Tomic, Viktorija, et al.
Publicado: (2014)

A7.5 In Vitro antibacterial activity against Gram-positive and Gram-negative pathogens in Asia - Tigecycline evaluation surveillance trial (T.E.S.T.)
Publicado: (2005)

High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can
por: Garnacho-Montero, José, et al.
Publicado: (2014)

Bismuth Drugs Reverse Tet(X)-Conferred Tigecycline Resistance in Gram-Negative Bacteria
por: Deng, Tian, et al.
Publicado: (2022)

Effect of pharmacokinetic/pharmacodynamic ratio on tigecycline clinical response and toxicity in critically ill patients with multidrug-resistant Gram-negative infections
por: Ruiz, Jesus, et al.
Publicado: (2020)

Temporal trends of the in vitro activity of tigecycline and comparator antibiotics against clinical aerobic bacterial isolates collected in Germany, 2006–2014: results of the Tigecycline Evaluation and Surveillance Trial (TEST)
por: Kresken, Michael, et al.
Publicado: (2016)

Rational use of tigecycline and tigecycline blood concentration monitoring in patients with severe infection
por: Yu, Meiling, et al.
Publicado: (2023)

Propranolol restores susceptibility of XDR Gram-negative pathogens to meropenem and Meropenem combination has been evaluated with either tigecycline or amikacin
por: Mabrouk, Samar S., et al.
Publicado: (2023)

490 High Dose Tigecycline for the Treatment of Multi-Drug Resistant Gram Negative Urinary Tract Infections
por: Sam, Sharon, et al.
Publicado: (2014)

Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection
por: Shin, Jung Ar, et al.
Publicado: (2012)

Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline
por: Wadi, Jamal Ahmad, et al.
Publicado: (2007)

Tigecycline Susceptibility and the Role of Efflux Pumps in Tigecycline Resistance in KPC-Producing Klebsiella pneumoniae
por: He, Fang, et al.
Publicado: (2015)

Efficacy and Safety of Colistin versus Tigecycline for Multi-Drug-Resistant and Extensively Drug-Resistant Gram-Negative Pathogens—A Meta-Analysis
por: Abushanab, Dina, et al.
Publicado: (2022)

Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens
por: Chen, Zihan, et al.
Publicado: (2018)

Tigecycline Induced Hyperpigmentation of the Skin
por: Vandecasteele, S. J., et al.
Publicado: (2016)

Benzydamine Reverses TMexCD-TOprJ-Mediated High-Level Tigecycline Resistance in Gram-Negative Bacteria
por: Tong, Ziwen, et al.
Publicado: (2021)

Evaluating the performance characteristics of different antimicrobial susceptibility testing methodologies for testing susceptibility of gram-negative bacteria to tigecycline
por: Babaei, Sima, et al.
Publicado: (2021)

A Novel Tigecycline Adjuvant ML-7 Reverses the Susceptibility of Tigecycline-Resistant Klebsiella pneumoniae
por: Sun, Lilan, et al.
Publicado: (2022)

Once Daily High Dose Tigecycline Is Optimal: Tigecycline PK/PD Parameters Predict Clinical Effectiveness
por: Baron, Jeffrey, et al.
Publicado: (2018)

Use of Carbapenems, Polymyxins, and Tigecycline in United States Children’s Hospitals, 2010–2014
por: Chiotos, Kathleen, et al.
Publicado: (2017)

High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria
por: De Pascale, Gennaro, et al.
Publicado: (2014)

Safety and effectiveness of tigecycline combination therapy in renal transplant patients with infection due to carbapenem-resistant gram-negative bacteria
por: Wang, Qin, et al.
Publicado: (2023)

Effects of tigecycline and doxycycline in porcine endotoxemia
por: Von Seth, M, et al.
Publicado: (2011)

Therapy of intracellular Staphylococcus aureus by tigecyclin
por: Kreis, Carolin A, et al.
Publicado: (2013)

The Transcriptomic Signature of Tigecycline in Acinetobacter baumannii
por: Li, Liping, et al.
Publicado: (2020)

Risk Factors for Tigecycline-Associated Hypofibrinogenemia
por: Liu, Jia, et al.
Publicado: (2021)

Resistance mechanisms of tigecycline in Acinetobacter baumannii
por: Sun, Chunli, et al.
Publicado: (2023)

Tigecycline Absorption Improved by Selected Excipients
por: Ziółkowski, Hubert, et al.
Publicado: (2023)

Intra-abdominal infection after tumor surgery: tigecycline combined with β-lactam antibiotics versus tigecycline alone
por: Cai, Xinfeng, et al.
Publicado: (2023)

In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii
por: Principe, Luigi, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_p5onrvvbupk1c8lq7p14557g1a